Login Register Cart 0
Generic placeholder image

Current Pharmacogenomics and Personalized Medicine

Editor-in-Chief

ISSN (Print): 1875-6921
ISSN (Online): 1875-6913

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Clinical Trial Participant's Perspectives on Genetic Research Data Re-uses for Future Research

Author(s): Revanasiddappa Devarinti* and Madiwalayya Shivkantayya Ganachari

Volume 21, Issue 1, 2024

Published on: 17 May, 2024

Page: [28 - 37] Pages: 10

DOI: 10.2174/0118756921305151240503075928

Price: $65

Abstract

Background: Clinical trial participants play a crucial role in advancing medical research, and the data generated from their participation can indeed be invaluable for future studies. However, the reuse of genetic or clinical research data comes with ethical challenges that need careful consideration. Here are some of the key ethical issues associated with the re-use of such data: Reusing data without clear informed consent raises issues of autonomy and respect for individuals' choices.

Objective: The main aim of this study is to assess the understanding of individuals involved in clinical trials regarding the sharing of genetic research information. Moreover, it seeks to explore the ethical issues and benefits linked with the use of genetic research data for future research initiatives.

Methods: A cross-sectional observational study was applied to assess Knowledge Attitude Practices of clinical trial participants on reuse of genetic research data.

Results: The majority 70% of clinical trial participants were unsure about the difficulties that may arise in future regarding the re-use of genomic data, with concerns about confidentiality being the most common.

Conclusion: The present study prioritized the involvement of clinical trial participants due to their critical role in both genetic and clinical research endeavors. There is a lack of awareness and understanding regarding the re-use of genetic research data and ethical issues among the trial participants. Researchers must take measures to de-identify or anonymize data to protect participants. There is a clear need for comprehensive awareness programs and guidelines aimed at all clinical trial stakeholders. These initiatives would ensure that researchers, participants, and other involved parties are well-informed and adhere to ethical standards when utilizing genetic data for subsequent research endeavors.

« Previous Next »
Graphical Abstract

[1]
Michelle M. Clinical trial participants’ Views of the risks and benefits of data sharing. N Engl J Med 2018; 378: 2202-11.
[http://dx.doi.org/10.1056/NEJMsa1713258]
[2]
Renegar G, Webster CJ, Stuerzebecher S, et al. Returning genetic research results to individuals: Points-to-consider. Bioethics 2006; 20(1): 24-36.
[http://dx.doi.org/10.1111/j.1467-8519.2006.00473.x] [PMID: 16680905]
[3]
Indian council of medical research guidelines. 2017. Available from: https://main.icmr.nic.in/guidelines?field_select_disease_tid=97
[4]
Vidgen ME, Kaladharan S, Malacova E, Hurst C, Waddell N. Sharing genomic data from clinical testing with researchers: Public survey of expectations of clinical genomic data management in Queensland, Australia. BMC Med Ethics 2020; 21(1): 119.
[http://dx.doi.org/10.1186/s12910-020-00563-6] [PMID: 33213438]
[5]
Indian Council of Medical Research. National guidelines for stem cell research. 2017. Available from: http://www.icmr.nic.in/guidelines
[6]
Lander ES, Linton LM, Birren B, et al. Initial sequencing and analysis of the human genome. Nature 2001; 409(6822): 860-921.
[http://dx.doi.org/10.1038/35057062] [PMID: 11237011]
[7]
Yakubu A, Tindana P, Matimba A, et al. Model framework for governance of genomic research and biobanking in Africa – A content description. AAS Open Res 2018; 1: 13.
[http://dx.doi.org/10.12688/aasopenres.12844.2] [PMID: 30714023]
[8]
Green ED, Watson JD, Collins FS. Human genome project: Twenty-five years of big biology. Nature 2015; 526(7571): 29-31.
[http://dx.doi.org/10.1038/526029a] [PMID: 26432225]
[9]
Industry Pharmacogenomics Working Group (I-PWG).. Understanding the intent, scope, and public health benefits of exploratory biomarker research. A guide for IRBs/IECs and investigational site staff. 2010. Available from: https://learning.eupati.eu/mod/book/tool/print/index.php?id=388
[10]
ICH E6(R1) – Guideline for good clinical practice. 1996. Available from: www.ich.org/LOB/media/MEDIA482.pdf
[11]
Amin L, Hashim H, Mahadi Z, Ismail K. Determinants of the willingness to participate in biobanking among Malaysian stakeholders in the Klang Valley. BMC Med Res Methodol 2018; 18(1): 163.
[http://dx.doi.org/10.1186/s12874-018-0619-2] [PMID: 30518344]
[12]
Swede H, Stone CL, Norwood AR. National population-based biobanks for genetic research. Genet Med 2007; 9(3): 141-9.
[http://dx.doi.org/10.1097/GIM.0b013e3180330039] [PMID: 17413418]
[13]
Amorim M, Silva S, Machado H, et al. Benefits and risks of sharing genomic data for research: Comparing the views of rare disease patients, informal carers and healthcare professionals. Int J Environ Res Public Health 2022; 19(14): 8788.
[http://dx.doi.org/10.3390/ijerph19148788] [PMID: 35886636]
[14]
Nuremberg code. Available from: http://ohsr.od.nih.gov/guidelines/nuremberg.html
[15]
Barnes M, Heffernan K. The “Future Uses” Dilemma: Secondary uses of data and materials by researchers for commercial research sponsors. Med Res Law Policy 2004; 3: 440-50.
[16]
Jones KH, Daniels H, Squires E, Ford DV. Public views on models for accessing genomic and health data for research: Mixed methods study. J Med Internet Res 2019; 21(8): e14384.
[http://dx.doi.org/10.2196/14384] [PMID: 31436163]
[17]
National Human Genome Research Institute 2018. Available from: https://www.genome.gov/sequencingcosts/
[18]
Naveed M, Ayday E, Clayton EW, et al. Privacy in the genomic era. ACM Comput Surv 2015; 48(1): 1-44.
[http://dx.doi.org/10.1145/2767007] [PMID: 26640318]
[19]
Sánchez MC, Clemente HJC, López GFJ. Public and patients’ perspectives towards data and sample sharing for research: An overview of empirical findings. J Empir Res Hum Res Ethics 2023; 18(5): 319-45.
[http://dx.doi.org/10.1177/15562646231212644] [PMID: 37936410]
[20]
ICH E15 Definitions for genomic biomarkers, pharmacogenomics, pharmacogenetics, genomic data and sample coding categories - Scientific guideline. 2008. Available from: https://www.ema.europa.eu/en/ich-e15-definitions-genomic-biomarkers-pharmacogenomics-pharmacogenetics-genomic-data-sample-coding-categories-scientific-guideline

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy